218 related articles for article (PubMed ID: 34854131)
1. Immunogenicity and tolerability of COVID-19 vaccination in peritoneal dialysis patients-A prospective observational cohort study.
Haase M; Lesny P; Haase-Fielitz A; Anderson M; Cloherty G; Stec M; Lucas C; Santos-Araujo C; Haarhaus M; Macario F
Semin Dial; 2022 May; 35(3):269-277. PubMed ID: 34854131
[TBL] [Abstract][Full Text] [Related]
2. Humoral immunogenicity and tolerability of heterologous ChAd/BNT compared with homologous BNT/BNT and ChAd/ChAd SARS-CoV-2 vaccination in hemodialysis patients : A multicenter prospective observational study.
Haase M; Lesny P; Anderson M; Cloherty G; Stec M; Haase-Fielitz A; Haarhaus M; Santos-Araújo C; Veiga PM; Macario F
J Nephrol; 2022 Jun; 35(5):1467-1478. PubMed ID: 35084719
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of a first dose of mRNA- or vector-based SARS-CoV-2 vaccination in dialysis patients: a multicenter prospective observational pilot study.
Lesny P; Anderson M; Cloherty G; Stec M; Haase-Fielitz A; Haarhaus M; Santos C; Lucas C; Macario F; Haase M
J Nephrol; 2021 Aug; 34(4):975-983. PubMed ID: 34050904
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis.
Schrezenmeier E; Bergfeld L; Hillus D; Lippert JD; Weber U; Tober-Lau P; Landgraf I; Schwarz T; Kappert K; Stefanski AL; Sattler A; Kotsch K; Dörner T; Sander LE; Budde K; Halleck F; Kurth F; Corman VM; Choi M
Front Immunol; 2021; 12():690698. PubMed ID: 34276681
[TBL] [Abstract][Full Text] [Related]
5. Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients.
Rabinowich L; Grupper A; Baruch R; Ben-Yehoyada M; Halperin T; Turner D; Katchman E; Levi S; Houri I; Lubezky N; Shibolet O; Katchman H
J Hepatol; 2021 Aug; 75(2):435-438. PubMed ID: 33892006
[TBL] [Abstract][Full Text] [Related]
6. The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients.
Zitt E; Davidovic T; Schimpf J; Abbassi-Nik A; Mutschlechner B; Ulmer H; Benda MA; Sprenger-Mähr H; Winder T; Lhotta K
Front Immunol; 2021; 12():704773. PubMed ID: 34220867
[TBL] [Abstract][Full Text] [Related]
7. Antibody Response and Safety After mRNA-1273 SARS-CoV-2 Vaccination in Peritoneal Dialysis Patients - the Vienna Cohort.
Beilhack G; Monteforte R; Frommlet F; Gaggl M; Strassl R; Vychytil A
Front Immunol; 2021; 12():780594. PubMed ID: 34925359
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis.
Yau K; Abe KT; Naimark D; Oliver MJ; Perl J; Leis JA; Bolotin S; Tran V; Mullin SI; Shadowitz E; Gonzalez A; Sukovic T; Garnham-Takaoka J; de Launay KQ; Takaoka A; Straus SE; McGeer AJ; Chan CT; Colwill K; Gingras AC; Hladunewich MA
JAMA Netw Open; 2021 Sep; 4(9):e2123622. PubMed ID: 34473256
[TBL] [Abstract][Full Text] [Related]
9. Anti-SARS-CoV-2 IgG antibody titer after BNT162b2 mRNA COVID-19 vaccination in Japanese patients who underwent renal replacement therapy, hemodialysis, peritoneal dialysis, and kidney transplantation.
Iwabuchi R; Harada M; Yamada A; Aomura D; Yamada Y; Sonoda K; Nakazawa H; Sakai K; Mizukami E; Hashimoto K; Kamijo Y
Clin Exp Nephrol; 2023 Aug; 27(8):660-671. PubMed ID: 37095343
[TBL] [Abstract][Full Text] [Related]
10. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
Front Immunol; 2022; 13():827306. PubMed ID: 35173736
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 Antibody Response After a Third Dose of the BNT162b2 Vaccine in Patients Receiving Maintenance Hemodialysis or Peritoneal Dialysis.
Bensouna I; Caudwell V; Kubab S; Acquaviva S; Pardon A; Vittoz N; Bozman DF; Hanafi L; Faucon AL; Housset P
Am J Kidney Dis; 2022 Feb; 79(2):185-192.e1. PubMed ID: 34508833
[TBL] [Abstract][Full Text] [Related]
12. Time-dependent evolution of IgG antibody levels after first and second dose of mRNA-based SARS-CoV-2 vaccination in haemodialysis patients: a multicentre study.
Santos-Araújo C; Mota Veiga P; Santos MJ; Santos L; Romãozinho C; Silva M; Lucas C; Duarte ML; Haarhaus M; Haase M; Macário F
Nephrol Dial Transplant; 2022 Jan; 37(2):375-381. PubMed ID: 34634116
[TBL] [Abstract][Full Text] [Related]
13. Local and Systemic Immunity Are Impaired in End-Stage-Renal-Disease Patients Treated With Hemodialysis, Peritoneal Dialysis and Kidney Transplant Recipients Immunized With BNT162b2 Pfizer-BioNTech SARS-CoV-2 Vaccine.
Piotrowska M; Zieliński M; Tylicki L; Biedunkiewicz B; Kubanek A; Ślizień Z; Polewska K; Tylicki P; Muchlado M; Sakowska J; Renke M; Sudoł A; Dąbrowska M; Lichodziejewska-Niemierko M; Smiatacz T; Dębska-Ślizień A; Trzonkowski P
Front Immunol; 2022; 13():832924. PubMed ID: 35935974
[TBL] [Abstract][Full Text] [Related]
14. Humeral and cellular immune responses to SARS-CoV-2 vaccination in patients on peritoneal dialysis.
Yu ZY; Lai CF; Lai TS; Yang SY; Chen SI; Lai MJ; Kang CM; Huang YT; Chen YT; Hsueh PR; Chen YM; Lin SL
J Formos Med Assoc; 2023 Sep; 122(9):922-931. PubMed ID: 36894486
[TBL] [Abstract][Full Text] [Related]
15. Humoral response to SARS-CoV-2 vaccination promises to improve the catastrophic prognosis of hemodialysis patients as a result of COVID-19: the COViNEPH Project.
Tylicki L; Biedunkiewicz B; Dąbrowska M; Ślizień W; Tylicki P; Polewska K; Rosenberg I; Rodak S; Dębska-Ślizień A
Pol Arch Intern Med; 2021 Sep; 131(9):797-801. PubMed ID: 34351091
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
17. Determination of SARS-CoV-2 IgG antibody levels in hematology-oncology patients after COVID-19 vaccination.
Özsoy M; Yalçin S; Varlibaş A; Çifci A; Cesur S; Aksoy A; Berkem R
Eur Rev Med Pharmacol Sci; 2024 Feb; 28(4):1624-1631. PubMed ID: 38436195
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and safety of COVID-19 vaccination in patients with primary Sjögren's syndrome.
Verstappen GM; de Wolff L; Arends S; Heiermann HM; van Sleen Y; Visser A; Terpstra JH; Diavatopoulos DA; van der Heiden M; Vissink A; van Baarle D; Kroese FGM; Bootsma H
RMD Open; 2022 Apr; 8(1):. PubMed ID: 35414631
[TBL] [Abstract][Full Text] [Related]
20. The DiaCoVAb Study in South Italy: Immune Response to SARS-CoV-2 Vaccination in Dialysis Patients.
Fucci A; Giacobbe S; Guerriero I; Suzumoto Y; D'Andrea EL; Scrima M; Nolli ML; Iervolino A; Chiuchiolo LA; Salvatore E; Renzulli R; La Peccerella L; Marra G; Liuzzi M; Santoro D; Zulli E; Gentile R; Clemente G; Capasso G
Kidney Blood Press Res; 2022; 47(7):467-474. PubMed ID: 35318291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
